Intravenous iron and recombinant human erythropoietin in cancer patients.

single-agent irinotecan. We concentrated on pretreatment levels since we wanted to determine if this “crude” measurement of glucuronidation activity could be used in clinical decision making when treating patients with irinotecan. Nonetheless, our database was limited in that we did not have routine bilirubin follow-up measurements available. We are intrigued by the results of Kramar et al, though would caution that they should be replicated in a larger patient population before advocating prophylactic granulocyte colonystimulating factor support (the result that 50% of patients with bilirubin 1.5 mg/dL experienced grade 3/4 neutropenia is based on a group of three patients).